Mark Talamonti to Infliximab
This is a "connection" page, showing publications Mark Talamonti has written about Infliximab.
Connection Strength
0.189
-
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018 Oct; 32(10):1737-1744.
Score: 0.148
-
The impact of methodological approaches for presenting long-term clinical data on estimates of efficacy in psoriasis illustrated by three-year treatment data on infliximab. Dermatology. 2010; 221 Suppl 1:43-7.
Score: 0.021
-
Efficacy of efalizumab in psoriasis patients previously treated with tumour necrosis factor blockers. Dermatology. 2009; 219(1):48-53.
Score: 0.020